AriBio

AriBio is a clinical-stage biotech company located in Seongnam, South Korea and was founded in 2010. The company's slogan "Developing novel therapies for neurodegenerative diseases" encompasses its core mission. With a US office based in San Diego overseeing global clinical operations and regulatory affairs, AriBio is strategically positioned for international growth. The company's lead asset, AR1001, is set to enter a global phase 3 program this year, indicating a significant milestone in its development. AriBio recently secured a noteworthy KRW100.00BVenture Round investment on 18 February 2022, with major contributions from Milestone, Meritz Securities, and Lambda Asset Management. This investment not only validates the company's potential but also provides substantial support for its upcoming endeavours in the biotechnology industry. AriBio's focus on addressing neurodegenerative diseases positions it as a promising player in the ongoing quest for novel therapies in this critical medical field.